- Additional Presentations Underscore Potency, Binding Capabilities for Antibody Pipeline And Novel Technologies -
SCOTTSDALE, Ariz., April 9 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. , a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of Non Hodgkin’s Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver.
“Preclinical data on DXL625 indicates the strong promise of this candidate as a prospective treatment for NHL and Chronic Lymphatic Leukemia (CLL), and we anticipate starting clinical trials in the near term,” said Dr. Thomas Kindt, Chief Scientific Officer of InNexus. “The AACR will also feature a scientific presentation on our novel, proprietary approach for creating ‘programmed’ self-binding properties into antibodies. The increased potency of the antibody resulting from this technique suggests a new way to enhance antibody performance.”
Jeff Morhet, Chairman and Chief Executive Officer of InNexus, said, “InNexus has executed a focused and accelerated development plan for DXL625, while efficiently discovering promising new therapeutic candidates and supportive technologies. InNexus remains a novel, and independent, ‘pure-play’ antibody development company--an unusual investment and commercial opportunity.”
InNexus’ AACR presentations are titled, “A Novel High Avidity Anti-CD20 With Markedly Increased Cytotoxicity Shows No Systemic Toxicity In The Cynomolgus Monkey At A Dose 100-Fold Above The Anticipated Therapeutic Dose”, (AACR# 1231) and “Oxidative Modification Of An Anti-CD20 Antibody Imparts Autophilic Binding Kinetics”, (AACR# 1230). Posters and company representatives will also be available within the AACR Antibody and Antibody Targets Session from 1:00-5:00 PM on April 19th in Hall B-F, Poster Section 12. The posters will also be available via the InNexus website beginning April 19th.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company’s control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.
CONTACT: Jeff Morhet, Chairman & Chief Executive Officer, or Dr. Thomas
Kindt, Chief Scientific Officer, both of InNexus Biotechnology Inc.,
+1-480-862-7500
Web site: http://www.ixsbio.com/
